Sympathoinhibition as a preferred second line treatment of obesity related hypertension

Project Details

StatusActive
Effective start/end date1/03/2029/02/24

Funding

  • Abbott Products Operations AG: AUD231,010.00
  • Abbott Products Operations AG: AUD275,551.00
  • Abbott Products Operations AG: AUD198,547.00
  • Abbott Products Operations AG: AUD106,471.00
  • Abbott Products Operations AG: AUD15,054.00